Skip to main content
. 2018 Dec 4;2018(12):CD011902. doi: 10.1002/14651858.CD011902.pub2

Menzies 2008.

Study characteristics
Patient sampling Study design: case series?
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: multicentre
Patient characteristics and setting Inclusion criteria: dermoscopic amelanotic (with no melanin pigmentation) or hypomelanotic (a melanin pigmentation area of < 25% of the total surface area or slightly pigmented but with no dark brown, deep blue, or black pigmentation) lesions. All melanomas included, and a random selection of melanocytic and non‐melanocytic lesions on a non‐melanoma to melanoma ratio of 3:1
Setting: multicentre
Prior testing: NR
Setting for prior testing: NR
Exclusion criteria: lesions were excluded because of poor image quality or because they did not fit within any of the defined pigmentation categories
Sample size (participants): NR
Sample size (lesions): 497
Participant characteristics: NR
Lesion characteristics: NR
Index tests Dermoscopy: 7PCL; Menzies; 3PCL (new algorithm for distinguishing melanoma from non‐melanoma and any malignant from benign lesions was also developed on 80% of sample and tested on 20% but numbers disease‐positive and ‐negative for the test set were NR to allow 2x2 to be estimated.)
Method of diagnosis: image‐based
Prior test data: NR
Diagnostic threshold: ≥ 3; Menzies standard threshold; ≥ 2
Diagnosis based on: single observer
Observer qualifications: dermatologist (assumed) (n = 12); clinicians experienced in dermoscopic evaluation scored 99 individual morphological features in approximately equal sample sizes
Experience in practice: NR
Experience with dermoscopy: high
Target condition and reference standard(s) Reference standard: histology and follow‐up (numbers NR; some naevi included that showed no changes following consecutive digital monitoring)
Target condition (final diagnoses)
Invasive melanoma 91; melanoma in situ 14; BCC 126; cSCC 4
Benign naevi 159; SN 11; SK 22; DF 17; BD 7; keratoacanthoma 1; AK 8; other 37
Flow and timing Excluded participants: none reported
Time interval to reference test: NR
Comparative  
Notes
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case‐control design avoided? Yes    
Did the study avoid inappropriate exclusions? No    
Are the included patients and chosen study setting appropriate? No    
Did the study avoid including participants with multiple lesions? Unclear    
    High High
DOMAIN 2: Index Test Dermoscopy ‐ image‐based
Were the index test results interpreted without knowledge of the results of the reference standard? Yes    
If a threshold was used, was it pre‐specified? Yes    
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? No    
Was the test applied and interpreted in a clinically applicable manner? No    
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes    
Was the test interpretation carried out by an experienced examiner? Yes    
    Low High
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear    
Expert opinion (with no histological confirmation) was not used as a reference standard Yes    
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear    
    Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference standard? Unclear    
Did all patients receive the same reference standard? No    
Were all patients included in the analysis? Yes    
If the reference standard includes clinical follow‐up of borderline/benign appearing lesions, was there a minimum follow‐up following application of index test(s) of at least: 3 months for melanoma or cSCC or 6 months for BCC?      
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?      
    High